Skip to main content
Erschienen in: Medical Oncology 3/2013

01.09.2013 | Original Paper

p14ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma

verfasst von: Radoslav Davidović, Jelena Sopta, Vesna Mandušić, Milena Krajnović, Maja Stanojević, Goran Tulić, Bogomir Dimitrijević

Erschienen in: Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53–p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16 INK4a /p14 ARF genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14 ARF gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14 ARF promoter. The results from the current study suggest significant impact of the p14 ARF gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53–p14 and Rb-p16 pathways in liposarcoma.
Literatur
1.
Zurück zum Zitat Dei Tos AP. Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol. 2000;4(4):252–66.PubMedCrossRef Dei Tos AP. Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol. 2000;4(4):252–66.PubMedCrossRef
2.
Zurück zum Zitat Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.PubMedCrossRef Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.PubMedCrossRef
3.
Zurück zum Zitat Nishio J, Iwasaki H, Nabeshima K, Naito M. Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas. Genet Res Int. 2011;2011:497148.PubMed Nishio J, Iwasaki H, Nabeshima K, Naito M. Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas. Genet Res Int. 2011;2011:497148.PubMed
4.
Zurück zum Zitat Haniball J, Sumathi VP, Kindblom LG, Abudu A, Carter SR, Tillman RM, et al. Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma. Sarcoma. 2011;2011:538085.PubMedCrossRef Haniball J, Sumathi VP, Kindblom LG, Abudu A, Carter SR, Tillman RM, et al. Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma. Sarcoma. 2011;2011:538085.PubMedCrossRef
5.
Zurück zum Zitat Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2007;109(12):2522–31.PubMedCrossRef Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2007;109(12):2522–31.PubMedCrossRef
6.
Zurück zum Zitat Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials. 2009;4(1):12–26.PubMedCrossRef Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials. 2009;4(1):12–26.PubMedCrossRef
7.
Zurück zum Zitat Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157–65.PubMedCrossRef Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157–65.PubMedCrossRef
8.
9.
Zurück zum Zitat Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770–83.PubMedCrossRef Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770–83.PubMedCrossRef
10.
Zurück zum Zitat Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17(17):5001–14.PubMedCrossRef Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17(17):5001–14.PubMedCrossRef
11.
Zurück zum Zitat Luo D, Zhang B, Lv L, Xiang S, Liu Y, Ji J, et al. Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas. Lab Invest. 2006;86(6):591–8. Luo D, Zhang B, Lv L, Xiang S, Liu Y, Ji J, et al. Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas. Lab Invest. 2006;86(6):591–8.
12.
Zurück zum Zitat Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264(1):42–55.PubMedCrossRef Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264(1):42–55.PubMedCrossRef
13.
Zurück zum Zitat Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989.
14.
Zurück zum Zitat Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821–6.PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821–6.PubMedCrossRef
15.
Zurück zum Zitat Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol. 2005;207(4):410–21.PubMedCrossRef Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol. 2005;207(4):410–21.PubMedCrossRef
16.
Zurück zum Zitat Tos APD, Piccinin S, Doglioni C, Vukosavljevic T, Mentzel T, Boiocchi M, et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol. 1997;151(6):1531–9. Tos APD, Piccinin S, Doglioni C, Vukosavljevic T, Mentzel T, Boiocchi M, et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol. 1997;151(6):1531–9.
17.
Zurück zum Zitat Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7(12):3977–87.PubMed Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7(12):3977–87.PubMed
18.
Zurück zum Zitat Smith TAGJ. Immunohistochemical analysis of p53 protein in myxoid/round cell liposarcomas of the extremities. Appl Immunohistochem. 1996;4(4):228–34. Smith TAGJ. Immunohistochemical analysis of p53 protein in myxoid/round cell liposarcomas of the extremities. Appl Immunohistochem. 1996;4(4):228–34.
19.
Zurück zum Zitat Dei Tos AP, Doglioni C, Piccinin S, Maestro R, Mentzel T, Barbareschi M, et al. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol. 1997;181(1):8–13.PubMedCrossRef Dei Tos AP, Doglioni C, Piccinin S, Maestro R, Mentzel T, Barbareschi M, et al. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol. 1997;181(1):8–13.PubMedCrossRef
20.
Zurück zum Zitat Perot G, Chibon F, Montero A, Lagarde P, de The H, Terrier P, et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol. 2010;177(4):2080–90.PubMedCrossRef Perot G, Chibon F, Montero A, Lagarde P, de The H, Terrier P, et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol. 2010;177(4):2080–90.PubMedCrossRef
21.
Zurück zum Zitat Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42(8):715–21.PubMedCrossRef Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42(8):715–21.PubMedCrossRef
22.
Zurück zum Zitat Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, et al. Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int J Cancer. 2000;87(5):654–8.PubMedCrossRef Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, et al. Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int J Cancer. 2000;87(5):654–8.PubMedCrossRef
23.
Zurück zum Zitat Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A, et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res. 2003;9(11):4132–8.PubMed Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A, et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res. 2003;9(11):4132–8.PubMed
24.
Zurück zum Zitat Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X, et al. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 2006;106(7):1602–9.PubMedCrossRef Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X, et al. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 2006;106(7):1602–9.PubMedCrossRef
25.
Zurück zum Zitat von Keyserling H, Kühn W, Schneider A, Bergmann T, Kaufmann AM. p16INK4a and p14ARF mRNA expression in Pap smears is age-related. Mod Pathol. 2011;25(3):465–70.CrossRef von Keyserling H, Kühn W, Schneider A, Bergmann T, Kaufmann AM. p16INK4a and p14ARF mRNA expression in Pap smears is age-related. Mod Pathol. 2011;25(3):465–70.CrossRef
26.
Zurück zum Zitat Herath NI, Kew MC, Walsh MD, Young J, Powell LW, Leggett BA, MacDonald GA. Reciprocal relationship between methylation status and loss of heterozygosity at the p14(ARF) locus in Australian and South African hepatocellular carcinomas. J Gastroenterol Hepatol. 2002;17(3):301–7.PubMedCrossRef Herath NI, Kew MC, Walsh MD, Young J, Powell LW, Leggett BA, MacDonald GA. Reciprocal relationship between methylation status and loss of heterozygosity at the p14(ARF) locus in Australian and South African hepatocellular carcinomas. J Gastroenterol Hepatol. 2002;17(3):301–7.PubMedCrossRef
27.
Zurück zum Zitat Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A, et al. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis. 2000;21(11):2057–64.PubMedCrossRef Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A, et al. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis. 2000;21(11):2057–64.PubMedCrossRef
28.
Zurück zum Zitat Foulkes WD, Flanders TY, Pollock PM, Haywardt NK. The CDKN2A (pl6) gene and human cancer. Mol Med. 1997;3(1):5–20.PubMed Foulkes WD, Flanders TY, Pollock PM, Haywardt NK. The CDKN2A (pl6) gene and human cancer. Mol Med. 1997;3(1):5–20.PubMed
29.
Zurück zum Zitat Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127(2):265–75.PubMedCrossRef Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127(2):265–75.PubMedCrossRef
30.
Zurück zum Zitat He M, Aisner S, Benevenia J, Patterson F, Harrison LE, Hameed M. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma. Pathol Res Pract. 2009;205(6):386–94.PubMedCrossRef He M, Aisner S, Benevenia J, Patterson F, Harrison LE, Hameed M. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma. Pathol Res Pract. 2009;205(6):386–94.PubMedCrossRef
31.
Zurück zum Zitat Futreal PA, Barrett JC, Wiseman RW. An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res. 1991;19(24):6977.PubMedCrossRef Futreal PA, Barrett JC, Wiseman RW. An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res. 1991;19(24):6977.PubMedCrossRef
Metadaten
Titel
p14ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma
verfasst von
Radoslav Davidović
Jelena Sopta
Vesna Mandušić
Milena Krajnović
Maja Stanojević
Goran Tulić
Bogomir Dimitrijević
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0682-9

Weitere Artikel der Ausgabe 3/2013

Medical Oncology 3/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.